MI Medicine International 2754-3242 2754-1304 D.A. Spandidos MI-2-6-00059 10.3892/mi.2022.59 Articles Early diagnosis of cerebral vasospasm associated with cerebral ischemia following subarachnoid hemorrhage: Evaluation of computed tomography perfusion and transcranial doppler as accurate methods TsolakiVasiliki 1 Aravantinou-FatorouAikaterini 2 GeorgakopoulouVasiliki Epameinondas 3 SpandidosDemetrios A. 4 PapalexisPetros 5 6 MathioudakisNikolaos 7 TarantinosKyriakos 8 TrakasNikolaos 9 SklapaniPagona 10 FotakopoulosGeorge 11 Department of Pulmonary and Critical Care Medicine, General University Hospital of Larisa, 41221 Larisa, Greece First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece Department of Infectious Diseases and COVID-19 Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece Laboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece Department of Biomedical Sciences, University of West Attica, 12243 Athens, Greece Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece First Department of Pulmonology, Sismanogleio Hospital, 15126 Athens, Greece Department of Biochemistry, Sismanogleio Hospital, 15126 Athens, Greece Department of Cytology, Mitera Hospital, 15123 Athens, Greece Department of Neurosurgery, General University Hospital of Larisa, 41221 Larisa, Greece Correspondence to: Dr Vasiliki Epameinondas Georgakopoulou, Department of Infectious Diseases and COVID-19 Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece vaso_georgakopoulou@hotmail.com xyl8807@163.com Nov-Dec 2022 02 11 2022 2 6 34 30 08 2022 01 11 2022 Copyright: © Tsolaki et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cerebral vasospasm (CV) constitutes a major post-operative complication and source of morbidity in cases of subarachnoid hemorrhage (SAH). The early detection of CV in SAH may be difficult both clinically and radiographically. The present pilot study thus aimed to evaluate the practicability of the technique in a tertiary healthcare setting and to assess the diagnostic effectiveness of various diagnostic computed tomography (CT) perfusion (CTP) aspects in predicting the clinical outcome of patients with SAH (traumatic and aneurysmal). A retrospective study including 34 patients in a tertiary care hospital was thus conducted. The results revealed that of the 34 patients, 18 (52.9%) were males, and the mean age was 54.4±18.5 years (16-85 years old; range, 69 years). In total, 15 (44.1%) patients had traumatic SAH following traumatic brain injury (TBI), 11 (33.3%) had aneurysmal SAH, and 8 patients (23.6%) presented with TBI without SAH as controls. CTP was performed on the third to the sixth day, and 15-20 min prior to CPT, a transcranial Doppler ultrasound was performed. Clinical outcomes were documented at 30 days using a CT scan and a complete neurological evaluation, including Glasgow Coma Scale assessment. The results of a multivariate analysis revealed that cerebral blood flow (CBF) was an independent factor for detecting an ischemic event in 1 month (P=0.003). On the whole, the present study demonstrates that CTP, and consequently CBF, is a considerable index that may identify the onset of cerebral ischemia in patients with SAH.

 subarachnoid hemorrhage computed tomography perfusion transcranial doppler cerebral vasospasm Funding: No funding was received. Introduction

Cerebral vasospasm (CV) or delayed cerebral ischemia (DCI) is the main complication and cause of morbidity following surgery in individuals that have a subarachnoid hemorrhage (SAH). Unfortunately, however, 16-65% of these patients, despite the use of different therapeutic procedures, consequently develop ischemia (1-4). A variety of strategies are employed to enhance cerebral blood flow (CBF) in patients with SAH who develop CV. Intra-aortic balloon counterpulsation, hyperdynamic therapy, intra-arterial and intrathecal drug infusion, as well as novel experimental techniques, such as endovascular treatment and different drugs or their combinations, may be helpful if treatment are commenced at an early stage. However, if a CV does not appear or treatment begins at a late stage, cerebral ischemia (CI) may occur even with optimal management (5).

Identifying CV (clinically or with angiography) at an early stage in SAH can be difficult and challenging (1,2). Although 40-70% of patients exhibit the substantiation of arterial narrowing (on a Doppler ultrasound or an angiography), only 20 to 30% present with DCI (1,2). Intra-arterial digital subtraction angiography (DSA) significantly performs as a screening device in patients whose symptoms and clinical findings are consistent with focal CI (6). However, when assessing the global vasculature using DSA, the detailed delineation of the calf vessels may not be obtained when numerous stenoses are present and constitute an invasive method. Computed tomography (CT) can reveal the amount of irreversibly damaged tissue (the ischemic core) (7-9), and it indicates that reperfusion therapy may not be necessary or may even be harmful when the ischemic core is large or the perfusion is damaged to a great extent (10,11). By contrast, CT perfusion (CTP) is able to identify damage which is not recognized by other methods and may be beneficial for the assessment of CI related to SAH (12). CTP can be used in daily practice, or it can be used as a separate diagnostic tool without the need for magnetic resonance imaging data to predict the outcomes of patients with SAH (13,14). In addition, available data on its association with other non-invasive techniques, such as transcranial Doppler (TCD) ultrasound are not sufficient (1,15,16).

In this respect, the present study was performed with an aim to evaluate the utility of the CTP procedure in the daily practice of a tertiary hospital for the early recognition of symptomatic vasospasm in preventing permanent neurological deterioration and to assess the diagnostic performance of this technique in the clinical outcomes of patients with SAH (traumatic and aneurysmal).

 Patients and methods <sec> <title>Study design and inclusion criteria

The present retrospective study included patients with spontaneous/aneurysmal or traumatic SAH i) who presented with Glasgow Coma Scale (GCS) scores of 15/15 to 4/15; and ii) whose CT scan demonstrated high-grade SAH according to neuroimaging damage degree (Fisher-IV), in a very early stage (48 h after the onset) of SAH, as well as patients presenting with traumatic brain injury (TBI) without SAH as controls, between July, 2018 and January, 2020 at the University Hospital of Larisa (Larisa, Greece). Patients with TBI without SAH were selected as controls, as TBI may be associated with the pathophysiology of ischemic post-traumatic events. The Institutional Review Board (IRB) of University of Thessaly, Greece/The School of Medicine/School of Health Sciences approved the study (IRB no. 2492/19-01-2015). The study was in line with the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). Written informed was obtained from all patients.

As the present study was retrospective, groups of patients whose parameters (such as blood pressure and intra- and extracranial artery stenosis), were the same and without any marked differences were included.

 Exclusion criteria

Patients with factors predisposed to CI apart from vasospasm (i.e., those with atrial fibrillation or other arrhythmias, diabetes mellitus, hyperlipidemia and hypotension) or with factors predisposed to bleeding (anticoagulant agents and severe liver impairment) were excluded. All participants were followed up for 30 days or until they were discharged from the hospital. Outcomes were evaluated at 30 days using a CT scan and a full neurological examination was performed, together with GCS assessment. The clinical outcome was categorized according to the presence of neurological or radiological evidence as normal, adverse (headache, change of consciousness, or others), or mortality.

 Treatments

During the 3rd to 6th day after SAH, CTP was performed in all the participants to identify a quantifiable index of CI after CV given that angiographically detectable cerebral artery constriction is most commonly present at 3-10 days after the onset. Cerebral blood volume (CBV) and cerebral blood flow (CBF) values were documented and assessed after receiving two contiguous 10-mm slices placed at the anatomical point of the basal ganglia with similar angulation as for native CT. A bolus of 50 ml of nonionic contrast medium (Imeron 400, Bracco Imaging Deutschland GmbH) accompanied by 30 ml of saline was then infused using a power injector at a flow rate of 4 ml/sec. Subsequently, 40 images were captured at each slice level at a rate of two images per second (120 kV, 110 mAs, 512x512 matrix). CTP color maps were assessed qualitatively using a visual grading scale, and CTP parameters were established utilizing software platforms (Perfusion CT, Siemens). A positive visual measurement was recorded for side-to-side discrepancies or obvious bilateral anomalies, which could suggest a decline in CBF, CBV, and mean transit time (MTT), which were related to the central volume principle: CBF=CBV/MTT (1,17). CBV was determined in milliliters of blood per 100 gm of brain and was established as the volume of blood flow for a certain amount of brain tissue (1,18). MTT was determined as the average time needed for blood to move through a certain volume of brain and was calculated in seconds (1).

Moreover, 15-20 min before CTP, TCD via a trans-temporal window was carried out to illustrate and assess flow velocities in the anterior cerebral artery (ACA), middle cerebral artery (MCA), posterior cerebral artery (PCA) and posterior communicating artery. Peak systolic velocity (PSV, in cm/sec), which is the maximum flow velocity value during systole, was calculated at the peak of the waveform. End-diastolic velocity (EDV, in cm/sec) was determined at the end of diastole, traditionally at the lowest point before the beginning of a new waveform, which is between 20 and 50% of the PSV value (1,19). The Lindegaard ratio, defined as MCA mean CBF velocity divided by extracranial internal carotid artery mean CBF velocity, was utilized as an indicator of systemic hemodynamic alterations. The mean flow velocity (in cm/sec) was calculated as the average of the edge frequency across a cardiac cycle, which was calculated as EDV plus one-third of the variance between PSV and EDV [MFV (cm/sec)=(PSV + 2EDV/3)] (1,19). A sonographic CV was defined as an MFV of >140 cm/sec in the MCA, ACA, and/or PCA or >90 cm/sec in the basilar artery. Pulsatility index (PI)=PSV-EDV/MFV was utilized as an index for intracranial pressure elevation (1,19).

 Statistical analysis

The normality of the distribution of variables was determined using the Shapiro-Wilk test. The data were non-parametric and were compared using the Mann-Whitney U test. To identify predictors of adverse events (adverse ischemic events), statistically significant factors were subsequently examined using Cox proportional hazards multivariate regression analysis. Receiver operating characteristic (ROC) analysis was presented to reveal the implementation of TCD or CTP indicators in recognition of unfavorable outcomes. A P-value of <0.05 was characterized as statistically significant. Statistical analysis was performed with the use of the Statistical Package for the Social Sciences (SPSS 11; SPSS, Inc.).

 Results

A total of 34 patients were enrolled in the present study (Table I). Of these, 15 patients were males (44.1%), and the median age was 50.00 years (interquartile range, 31 years). Of these patients, 15 patients (44.1%) had traumatic SAH following TBI, 11 patients (33.3%) had aneurysmal SAH and 8 patients (23.6%) presented with no SAH after TBI as controls. The outcomes and baseline characteristics of the study participants are presented in Table I. Overall, 12 patients (35.2%), who experienced some clinical symptoms, such as a decline in the level of consciousness or a worsening headache, were administered hypervolemic hypertensive and intra-arterial calcium channel therapy after early the identification of symptomatic vasospasm with CTP findings and were presented with permanent neurological deficits as detected using a CT scan after 1 month of follow-up.

The TCD and CTP data are presented in Tables II and III, respectively. In addition, in the 12 patients who presented with permanent neurological deficits, CTP revealed reduced CBF and prolonged MTT. TCD also revealed elevated PSVs and PIs in the same patients, apart from patient no. 4, whose right ACA PI was normal (=0.9). In addition, TCD revealed that the right ACA PI of patient no. 21 was normal (=1) with PSV=87 cm/sec and MFV=69 cm/sec, the right PCA PI of patient no. 25 was 1.2 with PSV=58 cm/sec and MFV=35 cm/sec, and the left MCA PI of patient no. 30 was normal (=0.8) with PSV=89 cm/sec and MFV=87 cm/sec.

<sec> <title>Diagnostics

ROC analysis demonstrated that, among the CTP and TCD variables, a CBF value <21.5 ml x 100 g-1 x min-1 with 92.9% sensitivity and 80% specificity and an MTT value >3.7 sec with 86% sensitivity and 80% specificity presented the optimal performance to diagnose adverse ischemic events at 1 month, as evaluated by an area-under-the-curve standard error [AUC(SE)] of 0.89(0.06), P=0.005 (Table IV and Fig. 1, Fig. 2, Fig. 3 and Fig. 4).

Univariate analysis performed with the use of the Mann-Whitney U test revealed that there was a statistically significant difference in the mean values of PSV, CBF, CBV and MTT between participants who developed adverse ischemic events and between those who did not develop adverse ischemic events (P<0.05, Table V).

Cox proportion hazards multivariate regression analysis (Table VI) revealed that CBF was an independent factor in detecting an ischemic events in 1 month (P=0.003).

 Discussion

The results of the present study suggest that CTP is obtainable in everyday practice, and it may provide valuable details about SAH-associated CV. Certainly, CTP, and mainly CBF and MTT, can help to recognize patients who develop delayed unfavorable ischemic incidents and are more precise than TCD at this point. Thus, the CTP constitutes a very hopeful diagnostic instrument for managing SAH.

DSA is the gold standard for identifying CV and different cerebrovascular entities (1,20,21). However, the invasiveness of the procedure and the radiation exposure require careful patient selection and preclude widespread use (15). In addition, a number of invasive procedures, such as intracerebral CBF-dimension and microdialysis, have been developed due to their significance in detecting CV in patients after SAH (15). Those methods eschew the hazards of setting and continuing monitoring with intracerebral probes, such as infection, and they are only accurate if the calculation is performed in an area of the brain that will eventually be affected by decreased perfusion (1,15). Furthermore, MR perfusion, CTP, positron emission tomography, Xenon CT and single-photon emission CT all permit tomographic CBF evaluation. However, CTP is currently the most commonly used and studied imaging technique (22). A range of cut-off values associated with DCI has been mentioned, counting an MTT value >5.0-6.4 sec or a local CBF value <25-40 ml x 100 g-1 x min-1 (1,23).

The present study detected two separate major types of patients depending on their CTP and TCD data. The first profile was related to the clinical outcomes without ischemic damage in the CT scan at these locations, whereas the second one was related to unfavorable clinical outcomes with ischemic damage in the CT scan. In the first profile, the majority of patients had CTP that indicated no vasospasm or mild vasospasm according to the CBF and MTT values; this was observed in patient nos. 2 and 5. In patient no. 2, CTP revealed only delayed MTT from 7.3 to 10 sec and TCD revealed elevated PIs (0.9 in both right and left ACAs), indicating severe vasospasm. In patient no. 5, CTP demonstrated a decrease in CBF with delayed MTT, and TCD demonstrated elevated PIs in the right and left MCAs (1.4 and 1.3, respectively) and the left PCA (1.6), indicating mild vasospasm. On the other hand, 12 patients with the second profile, had CTP that illustrated substantial vasospasm with clinically and radiologically evident infarct lesions (Table I); however, PI values in TCD had a range between normal and 1.3, which is in agreement mainly with mild or no vasospasm (i.e., patient nos. 1, 3, 4, 21, 25 and 30). For patient no. 1, CTP demonstrated a decreased CBF value (in the right and left frontal, as well as left parietal areas), normal CBV values, and delayed MTT (7.4 to 10.5 sec), and TCD revealed a mean PI value of 1.5. In patient no. 3, CTP revealed decreased CBF and CBV values in the right frontal and parietal areas and delayed MTT mostly in the left part (7.4 to 10.9 sec), and TCD revealed a mean PI value of 1.2. In patient no. 4, CTP revealed reduced CBF and delayed MTT in the left from 7.4 to 8.7 sec, and TCD revealed a mean PI value of 1.1 (Tables II and III).

These findings indicate that CTP indices (CBF and MTT) presented a better dispersion in ROC analysis in comparison with TCD values (Table IV). CBF represents the blood flow in the brain, and any decrease in its value is strongly connected with the incidence and severity of vasospasm, which constitutes an important predictor variable of clinical outcome as well. CTP parameters (CBF and MTT) appear to be associated quite well with CI, although focal flow reduction can also be presented as a result of brain damage, retraction, or perihematomal brain impairment (1,5). On the contrary, TCD provides considerable information about the flow changes in an arterial segment and, based on the spectral models in a range of nearby intracranial arteries, it can identify CV in the MCA (24) and may possibly help as a comparatively simple screening technique of the vasospasm; however, some authors were reluctant to report any association between TCD and angiographic evidence in patients with CV (1,25,26). Additionally, TCD ultrasonography encounters both anatomical and technical limitations and is an operator-dependent technique (27).

CTP has been applied for the assessment of CI with sensitivity between 74.1 and 84% and specificity between 79 and 93.0% (28,29). In the present study, all regions with decreased CBF or prolonged MTT were associated with delayed ischemic unfavorable incidents, i.e., CBF [AUC (SE)] of 0.89(0.06), P=0.005, and MTT [AUC(SE)] of 0.82(0.07), P=0.001. This finding is in agreement with previous reports stating that a CBF reduction may suggest permanent ischemic lesions with a CBF threshold <25 ml x 100 g-1 x min-1. In addition, when a CBF decrease is associated with a CBV value <2 ml x 100 g-1 or with an increased MTT value >145%, core ischemia or penumbra can be identified (29). In the present study, a CBF threshold of 21.5 ml x 100 g-1 x min-1 and an MTT value >3.7 sec with 80 sensitivity and 100% specificity for CBF and 86% sensitivity and 80% specificity for MTT, which were calculated after an aneurysmal or traumatic SAH and they were similar to the literature (29), detected an unfavorable ischemic incident at 1 month. Previous studies have reported that a reduced CBF with normal or raised CBV may also indicate hemodynamic hypo-perfusion without real infarction damage in reaction to the autoregulation (1,30).

MTT alone may indicate mild to moderate vasospasm, whereas a MTT delay related to CBF and/or CBV changes may predict severe vasospasm (30). In the present study, all participants who obtained the aforementioned triad had late unfavorable ischemic events; however, no patients had MTT prolongation without any other CTP abnormalities, and therefore, the value of MTT as a stand-alone indicator could not be confirmed. Furthermore, in the present study, multivariable analysis revealed that MTT prolongation was not an independent factor for the diagnosis of ischemia at 1 month (P=0.614) and was only associated with CBF abnormalities that were related to clinical and CT indications of ischemia.

It is worth mentioning that imaging technology in healthcare facilities has become more widely available worlwide over time. Furthermore, the amount to which technology availability has changed varies across different areas with some areas expand and contract through time, whereas others expand and contract faster (31). As regards SAH, consecutive TCD measurements and the calculation of the hemispheric index are currently routinely used in several neurointensive care units. A regards the CTP, it requires the transportation of the patient out of the intensive care unit, limiting the clinical relevance of this method for monitoring (32).

A strong point of the present study is that it evaluated the utility of the CTP procedure in the daily practice of a tertiary hospital for the early recognition of symptomatic vasospasm in preventing permanent neurological deterioration. The present study also assessed the diagnostic performance of this technique in the clinical outcomes, not only of patients with aneurysmal, but and traumatic SAH in the first 24 h. This expansion allows for the better evaluation and understanding of the complex vasospasm entity.

The present study has certain limitations. It was a small, single-center study. In addition, factors such as the ethnic origin and the quality of different CT instruments vary between studies. Therefore, firm conclusions regarding the role of CTP in the management of SAH cannot be reached. However, the findings presented herein may serve as a basis for future more extensive multi-centered clinical studies with more homogeneous samples formed by aneurysmal SAH, along with comparing CPT to angiogram studies and assessing whether CBF predicts the response to vasospasm treatment.

In conclusion, the data of the present study demonstrated that the combination of CTP and TCD was instrumental in diagnosing ischemic events. In patients with CV, TCD alone was unable to achieve a good association with angiographic results. On the other hand, CTP demonstrated better precision, and mainly, CBF was a considerable index that could identify the extent of CI precociously in patients experiencing SAH; thus, it may allow intervention to prevent permanent neurological deterioration, either through the accentuation of hypervolemic hypertensive therapy, intra-arterial calcium channel administration, or intracranial angioplasty. MTT prolongation was not an independent factor, and only its relation with CBF abnormalities was associated with clinical and CT evidence of ischemia.

 Acknowledgements

Not applicable.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

GF, AAF and VEG conceptualized the study. VEG, AAF, PP, PS, NT, VT, NM and KT made substantial contributions to data analysis and interpretation, and wrote and prepared the draft of the manuscript. DAS, VEG and GF analyzed the data and provided critical revisions. VEG and GF confirm the authenticity of all the data. All authors contributed to manuscript revision and have read and approved the final version of the manuscript.

 Ethics approval and consent to participate

The Institutional Review Board (IRB) of University of Thessaly, Greece/The School of Medicine/School of Health Sciences approved the study (IRB no. 2492/19-01-2015). The study was in line with the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). Written informed was obtained from the patients.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References FotakopoulosGMakrisDKotliaPKapsalakiEPapanikolaouJGeorgiadisIZakynthinosEFountasKThe value of computed tomography perfusion & transcranial doppler in early diagnosis of cerebral vasospasm in aneurysmal & traumatic subarachnoid hemorrhageFuture Sci OA4FSO31320183005779010.4155/fsoa-2018-0015 KoNURajendranPKimHRutkowskiMPawlikowskaLKwokPYHigashidaRTLawtonMTSmithWSZaroffJGYoungWLEndothelial nitric oxide synthase polymorphism (-786T->C) and increased risk of angiographic vasospasm after aneurysmal subarachnoid hemorrhageStroke391103110820081830916910.1161/STROKEAHA.107.496596 DumontASDumontRJChowMMLinCLCalisanellerTLeyKFKassellNFLeeKSCerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammationNeurosurgery5312313320031282388110.1227/01.neu.0000068863.37133.9e StarkeRMKimGHKomotarRJHickmanZLBlackEMRosalesMBKellnerCPHahnDKOttenMLEdwardsJEndothelial nitric oxide synthase gene single-nucleotide polymorphism predicts cerebral vasospasm after aneurysmal subarachnoid hemorrhageJ Cereb Blood Flow Metab281204121120081831973210.1038/jcbfm.2008.11 FrancoeurCLMayerSAManagement of delayed cerebral ischemia after subarachnoid hemorrhageCrit Care2027720162773768410.1186/s13054-016-1447-6 FoleyWDSmithDFMildeMWLawsonTLTowneJBBandykDFIntravenous DSA examination of patients with suspected cerebral ischemiaRadiology1516516591984637188910.1148/radiology.151.3.6371889 MuirKWBaird-GunningJWalkerLBairdTMcCormickMCouttsSBCan the ischemic penumbra be identified on noncontrast CT of acute stroke?Stroke382485249020071767370810.1161/STROKEAHA.107.484592 MurphyBDFoxAJLeeDHSahlasDJBlackSEHoganMJCouttsSBDemchukAMGoyalMAvivRIIdentification of penumbra and infarct in acute ischemic stroke using computed tomography perfusion-derived blood flow and blood volume measurementsStroke371771177720061676318210.1161/01.STR.0000227243.96808.53 WintermarkMWarachSJSTIR and Virtual International Stroke Trials Archive (VISTA)-Imaging InvestigatorsAcute stroke imaging research roadmap II and international survey of acute stroke imaging capabilities: We need your help!AJNR Am J Neuroradiol34167120132386816010.3174/ajnr.A3698 CampbellBCChristensenSButcherKSGordonIParsonsMWDesmondPMBarberPALeviCRBladinCFDe SilvaDARegional very low cerebral blood volume predicts hemorrhagic transformation better than diffusion-weighted imaging volume and thresholded apparent diffusion coefficient in acute ischemic strokeStroke41828820101995953710.1161/STROKEAHA.109.562116 YassiNParsonsMWChristensenSSharmaGBivardADonnanGALeviCRDesmondPMDavisSMCampbellBCPrediction of poststroke hemorrhagic transformation using computed tomography perfusionStroke443039304320132400304310.1161/STROKEAHA.113.002396 ProvenzaleJMShahKPatelUMcCroryDCSystematic review of CT and MR perfusion imaging for assessment of acute cerebrovascular diseaseAJNR Am J Neuroradiol291476148220081858341010.3174/ajnr.A1161 DerexLNighoghossianNHermierMAdeleinePBerthezèneYPhilippeauFHonnoratJFromentJCTrouillasPInfluence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activatorJ Neurol Sci2253920041546507910.1016/j.jns.2004.05.020 ParsonsMWBarberPAChalkJDarbyDGRoseSDesmondPMGerratyRPTressBMWrightPMDonnanGADavisSMDiffusion- and perfusion-weighted MRI response to thrombolysis in strokeAnn Neurol51283720021178298110.1002/ana.10067 KunzeEPhamMRaslanFStetterCLeeJYSolymosiLErnestusRIVinceGHWestermaierTValue of perfusion CT, transcranial doppler sonography, and neurological examination to detect delayed vasospasm after aneurysmal subarachnoid hemorrhageRadiol Res Pract201223120620122305014610.1155/2012/231206 WestermaierTPhamMStetterCWillnerNSolymosiLErnestusRIVinceGHKunzeEValue of transcranial doppler, perfusion-CT and neurological evaluation to forecast secondary ischemia after aneurysmal SAHNeurocrit Care2040641220142398259710.1007/s12028-013-9896-0 MeierPZierlerKLOn the theory of the indicator-dilution method for measurement of blood flow and volumeJ Appl Physiol673174419541317445410.1152/jappl.1954.6.12.731 KonstasAAGoldmakherGVLeeTYLevMHTheoretic basis and technical implementations of CT perfusion in acute ischemic stroke, part 1: Theoretic basisAJNR Am J Neuroradiol3066266820091927010510.3174/ajnr.A1487 LysakowskiCWalderBCostanzaMCTramèrMRTranscranial doppler versus angiography in patients with vasospasm due to a ruptured cerebral aneurysm: A systematic reviewStroke322292229820011158831610.1161/hs1001.097108 ChaudharySRKoNDillonWPYuMBLiuSCriquiGIHigashidaRTSmithWSWintermarkMProspective evaluation of multidetector-row CT angiography for the diagnosis of vasospasm following subarachnoid hemorrhage: A comparison with digital subtraction angiographyCerebrovasc Dis2514415020081807346810.1159/000112325 YaoGELiQJiangXJLiuJLiJLZhangLLLiLLZhangJXiePVasospasm after subarachnoid hemorrhage: A 3D rotational angiography studyActa Neurochir Suppl11022122520112112547510.1007/978-3-7091-0356-2_40 CremersCHvan der SchaafICWensinkEGrevingJPRinkelGJVelthuisBKVergouwenMDCT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysisJ Cereb Blood Flow Metab3420020720142428174410.1038/jcbfm.2013.208 SanelliPCUgorecIJohnsonCETanJSegalAZFinkMHeierLATsiourisAJComunaleJPJohnMUsing quantitative CT perfusion for evaluation of delayed cerebral ischemia following aneurysmal subarachnoid hemorrhageAJNR Am J Neuroradiol322047205320112196049510.3174/ajnr.A2693 FontanellaMValfrèWBenechFCarlinoCGarbossaDFerrioMPerezRBerardinoMBradacGDucatiAVasospasm after SAH due to aneurysm rupture of the anterior circle of Willis: Value of TCD monitoringNeurol Res3025626120081776781110.1179/016164107X229939 BornsteinNMNorrisJWTranscranial doppler sonography is at present of limited clinical valueArch Neurol51105710591994794500510.1001/archneur.1994.00540220105022 SteinmeierRLaumerRBondárIPriemRFahlbuschRCerebral hemodynamics in subarachnoid hemorrhage evaluated by transcranial doppler sonography. Part 2. Pulsatility indices: Normal reference values and characteristics in subarachnoid hemorrhageNeurosurgery3310181993835582510.1227/00006123-199307000-00002 WashingtonCWZipfelGJParticipants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid HemorrhageDetection and monitoring of vasospasm and delayed cerebral ischemia: A review and assessment of the literatureNeurocrit Care1531231720112174849910.1007/s12028-011-9594-8 DankbaarJWde RooijNKVelthuisBKFrijnsCJRinkelGJvan der SchaafICDiagnosing delayed cerebral ischemia with different CT modalities in patients with subarachnoid hemorrhage with clinical deteriorationStroke403493349820091976270310.1161/STROKEAHA.109.559013 GreenbergEDGoldRReichmanMJohnMIvanidzeJEdwardsAMJohnsonCEComunaleJPSanelliPDiagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: A meta-analysisAJNR Am J Neuroradiol311853186020102088474810.3174/ajnr.A2246 WintermarkMFlandersAEVelthuisBMeuliRvan LeeuwenMGoldsherDPinedaCSerenaJvan der SchaafIWaaijerAPerfusion-CT assessment of infarct core and penumbra: Receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric strokeStroke3797998520061651409310.1161/01.STR.0000209238.61459.39 BakerLBirnbaumHGeppertJMisholDMoyneurEThe relationship between technology availability and health care spending. Health Aff (Millwood) Suppl Web Exclusives: W3-537-551, 2003. SpringborgJBFrederiksenHJEskesenVOlsenNVTrends in monitoring patients with aneurysmal subarachnoid haemorrhageBr J Anaesth9425927020051551635510.1093/bja/aei004

ROC curve for CBF predicting an ischemic event at 1 month. AUC, 0.896. AUC, area under the curve; CBF, celebral blood flow; ROC, receiver operative characteristic.

ROC curve for MTT predicting an ischemic event at 1 month. AUC, 0.829. AUC, area under the curve; MTT, mean transit time; ROC, receiver operative characteristic.

ROC curve for PI predicting an ischemic event at 1 month. AUC, 0.671. AUC, area under the curve; PI, pulsatility; ROC, receiver operative characteristic.

ROC curve for PSV predicting an ischemic event at 1 month. AUC, 0.727. AUC, area under the curve; PSV, peak systolic velocity; ROC, receiver operative characteristic.

Baseline characteristics of the patients and clinical outcomes.

Patient no. Age, years Sex Cause of admission Fisher scale aSAH or tSAH GCS of admission Clinical symptoms before TCD or CT perfusion attributed to CV Intervention to prevent permanent neurological deterioration Radiologic finding (CT scan) Clinical outcome
1 68 M TBI aEDH 2 + 8 Decline in level of consciousness, worsening headache HHTh Ischemic lesion to the left parietal lobe (posterior limb of the left internal capsule) Right foot palsy
2 16 M TBI 2 + 13     -  
3 68 F Pcom aneurysm 4 + 13 Worsening headache HHTh and ICaChA Ischemic lesion to the right temporo-parietal Left foot palsy
4 41 M Acom aneurysm 3 + 12 Worsening headache HHTh and ICaChA Small area with ischemic lesion to the right frontal Emotional disturbances
5 55 F Left MCA aneurysm 3 + 14   HHTh    
6 69 M TBI non SAH 1 + 7        
7 85 F TBI non SAH 1 + 13        
8 45 F TBI 2 + 15        
9 67 F TBI non SAH 1 + 15        
10 34 F TBI non SAH 1 + 15        
11 81 M Left MCA aneurysm 3 + 13 Worsening headache HHTh and ICaChA Ischemic lesion left fronto-parietal Right hand palsy
12 79 F TBI 2 + 14        
13 75 M TBI, aEDH 2 + 12   HHTh and ICaChA Ischemic lesion right frontal Emotional disturbances
14 66 F TBI 2 + 15        
15 49 F TBI non SAH 1 _ 15        
16 54 F TBI 2 + 14        
17 55 M Right PCA aneurysm 4 + 7 Worsening headache HHTh and ICaChA Ischemic lesion right occipital Visual disturbances
18 78 F TBI 2 + 15        
19 37 F TBI 2 + 13        
20 25 F TBI 2 + 15        
21 32 M Right MCA aneurysm 3 + 13 Worsening headache HHTh and ICaChA Ischemic lesion right fronto-parietal Left foot palsy
22 62 F TBI non SAH 1 _ 15        
23 27 F TBI 2 + 14        
24 37 M TBI 2 + 14 Worsening headache   Ischemic lesion left frontal Emotional disturbances
25 56 M Right PCA aneurysm 3 + 12 Decline in level of consciousness, worsening headache HHTh and ICaChA Ischemic lesion right parieto-occipital Left foot palsy
26 51 F TBI 2 + 13        
27 23 F TBI non SAH 1 _ 15        
28 69 F TBI 2 + 14        
29 67 M Left MCA aneurysm 3 + 15 Worsening headache HHTh and ICaChA Ischemic lesion left parietal Right hand palsy
30 46 M Left ACA aneurysm 4 + 8 Decline in level of consciousness, worsening headache HHTh and ICaChA Ischemic lesion left fronto-parietal Right foot palsy
31 45 F TBI 2 + 14        
32 71 M TBI 2 + 15        
33 74 M Right ACA aneurysm 3 + 14 Worsening headache HHTh and ICaChA Ischemic lesion Emotional disturbances
34 43 M TBI non SAH 1 _ 14     right frontal  

SAH, subarachnoid hemorrhage; aSAH, aneurismal subarachnoid hemorrhage; tSAH, traumatic subarachnoid hemorrhage; M, male; F, female; GCS, Glashow Coma Scale; MCA, middle cerebral artery; ACA, anterior cerebral artery; Acom, anterior communicate artery; Pcom, posterior communicate artery; PCA, posterior cerebral artery; TBI, traumatic brain injury; aEDH, acute epidural hematoma; CT, computer tomography; HHTh, hypervolemic hypertensive therapy; ICaChA, intraarterial calcium channel administration; TCD, transcranial doppler; CV, cerebral vasospasm.

Transcranial Doppler parameters.

  Patient no.
Parameters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
PCA (left)                                  
     -PSV (cm/sec) 81 63 134 118 121 57 56 50 56 143 63 48 71 106 64 107 95
     -EDV (cm/sec) 34 30 32 28 30 17 15 17 15 54 16 19 32 51 19 24 18
     -MFV (cm/s) 49 42 66 58 53 28 28 36 41 84 42 29 45 69 50 75 77
     -PI (cm/sec) 0.9 0.7 1.5 1.5 1.6 1.3 1.4 0.9 1 1 0.7 1 0.8 0.8 0.9 1.1 1
PCA (right)                                  
     -PSV (cm/sec) 98 68 87 94 86 45 42 48 52 208 42 120 82 81 56 117 191
     -EDV (cm/sec) 19 36 35 30 40 15 16 33 21 86 30 24 47 34 13 15 22
     -MFV (cm/sec) 46 47 49 52 54 25 26 15 44 127 26 56 59 49 43 85 105
     -PI (cm/sec) 1.7 0.7 1.1 1.2 0.8 1.2 1 1 0.7 0.9 1 1 0.6 0.9 1 1.2 1.6
MCA (left)                                  
     -PSV (cm/sec) 91 106 118 199 168 59 64 59 62 126 189 76 106 63 58 84 93
     -EDV (cm/sec) 34 51 31 74 46 18 19 15 22 48 23 27 51 30 21 13 19
     -MFV (cm/sec) 53 69 60 116 87 32 35 48 41 74 110 44 69 42 61 118 82
     -PI (cm/sec) 1.0 0.8 1.4 1.1 1.3 1.3 1.2 0.9 1 1 1.5 1.1 0.8 0.7 0.6 0.6 0.9
MCA (right)                                  
     -PSV (cm/sec) 71 82 113 188 190 81 77 61 59 165 88 82 91 42 69 87 76
     -EDV (cm/sec) 32 47 33 64 49 24 27 17 21 89 40 29 34 16 16 21 15
     -MFV (cm/sec) 45 59 60 106 96 43 43 62 47 114 56 46 53 26 75 82 67
     -PI (cm/sec) 0.8 0.6 1.3 1.1 1.4 1.3 1.1 0.7 0.8 0.6 0.8 1.1 1 1 0.7 0.8 0.9
ACA (left)                                  
     -PSV (cm/sec) 138 88 94 143 126 83 79 48 47 81 168 88 145 75 74 91 79
     -EDV (cm/sec) 28 40 26 54 48 22 24 19 19 24 28 40 73 37 21 19 17
     -MFV (cm/sec) 64 56 48 84 74 43 42 36 35 43 82 56 98 50 75 80 68
     -PI (cm/sec) 1.7 0.9 1.4 1.0 1 1.4 1.3 0.8 0.8 1.3 1.7 0.8 0.7 0.7 0.7 0.9 0.9
ACA (right)                                  
     -PSV (cm/sec) 468 145 190 208 165 76 82 46 49 57 145 126 160 77 87 86 81
     -EDV (cm/sec) 77 73 79 86 89 27 29 15 21 13 73 48 19 27 19 18 12
     -MFV (cm/sec) 208 98 119 127 114 44 46 34 28 28 98 74 88 43 75 85 98
     -PI (cm/sec) 1.9 0.9 0.9 0.9 0.6 1.1 1.1 0.9 1 1.1 0.7 1 1.6 1.1 0.9 0.8 0.7
Total PSV (cm/sec) (mean) 157.8 92 122.6 158.3 142.6 66.8 66.6 52 54.1 130 115.8 90 109.1 74.0 68 95.3 102.5
Total PI (cm/sec) (mean) 1.5 0.7 1.2 1.1 1.1 1.2 1.1 0.8 0.8 0.9 1.0 1.0 0.9 0.8 0.8 0.9 1.0
     PCA (left)                                  
     -PSV (cm/sec) 67 59 110 75 67 76 64 102 110 120 97 86 91 89 77 67 98
     -EDV (cm/sec) 15 18 23 27 29 15 21 13 73 48 19 27 19 14 27 21 25
     -MFV (cm/sec) 57 45 72 43 42 61 39 127 37 80 70 65 90 125 55 65 73
     -PI (cm/sec) 0.9 0.9 1.2 1.1 0.9 1 1.1 0.7 1 0.9 1.1 0.9 0.8 0.6 0.9 0.7 1
PCA (right)                                  
     -PSV (cm/sec) 78 64 107 46 49 57 145 58 83 79 48 47 81 168 88 145 75
     -EDV (cm/sec) 21 16 19 29 15 21 24 16 48 22 24 19 19 24 28 35 29
     -MFV (cm/sec) 71 68 67 24 37 40 121 35 43 81 34 40 68 160 60 122 57
     -PI (cm/sec) 0.8 0.7 1.3 0.7 0.9 0.9 1 1.2 0.8 0.7 0.7 0.7 0.9 0.9 1 0.9 0.8
MCA (left)                                  
     -PSV (cm/sec) 87 71 99 77 61 99 165 88 82 91 142 179 89 110 98 103 95
     -EDV (cm/sec) 19 12 18 21 13 41 48 19 27 19 14 24 19 35 38 32 29
     -MFV (cm/sec) 68 73 54 70 68 82 167 76 61 72 160 86 87 68 66 88 94
     -PI (cm/sec) 1 0.8 1.5 0.8 0.7 0.7 0.7 0.9 0.9 1 0.8 1.8 0.8 1.1 0.9 0.8 0.7
MCA (right))                                  
     -PSV (cm/sec) 78 69 89 75 67 76 64 102 110 120 97 86 91 89 77 67 101
     -EDV (cm/sec) 16 18 12 17 21 23 19 25 20 36 17 22 24 15 21 14 20
     -MFV (cm/sec) 68 51 85 72 46 75 75 85 112 105 86 91 74 82 70 53 115
     -PI (cm/sec) 0.9 1 0.9 0.8 1 0.7 0.6 0.9 0.8 0.8 0.9 0.7 0.9 0.9 0.8 1 0.7
ACA (left)                                  
     -PSV (cm/sec) 67 75 67 76 64 102 191 102 110 120 97 86 67 102 110 120 97
     -EDV (cm/sec) 16 25 20 16 17 22 17 17 21 23 19 25 21 20 46 37 22
     -MFV (cm/sec) 56 55 58 60 67 88 102 106 111 107 111 67 51 91 71 103 75
     -PI (cm/sec) 0.9 0.9 0.8 1 0.7 0.9 1.7 0.8 0.8 0.9 0.7 0.9 0.9 0.9 0.9 0.8 1
ACA (right)                                  
     -PSV (cm/sec) 86 110 112 87 82 46 49 57 145 126 160 67 76 64 102 193 102
     -EDV (cm/sec) 18 29 32 18 29 15 21 13 73 48 39 27 19 18 29 23 32
     -MFV (cm/sec) 77 90 114 69 40 18 35 62 58 111 134 44 43 51 81 100 85
     -PI (cm/sec) 0.9 0.9 0.7 1 1.3 1.7 0.8 0.7 0.7 0.7 0.9 0.9 1.3 0.9 0.9 1.7 0.8
Total PSV (cm/sec) 77.1 74.6 97.3 72.6 65 76 113 84.8 106.6 109.3 106.8 91.8 82.5 103.6 92 115.8 94.6
Total PI (cm/sec) 0.9 0.8 1.0 0.9 0.9 0.9 0.9 0.8 0.8 0.8 0.8 0.9 0.9 0.8 0.9 0.9 0.8

TCD, transcranial doppler; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; PSV, peak systolic velocity; EDV, end-diastolic velocity; MFV, mean flow velocity; PI, pulsatility index.

CT perfusion (white matter) parameters.

  Patient no.
Parameters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
CBV (mlblood/100 gtissue)                                  
     Right                                  
          Frontal 2.8 3.9 1.4 2.3 3.1 3.8 4.1 1.4 2.2 1.3 1.6 2.9 0.1 2.0 1.4 1.9 0.6
          Parietal 4.8 4.6 2.2 2 4.4 3.6 3.7 1.5 2.0 1.1 1.8 2.7 0.1 1.0 1.0 2.1 0.7
          Occipital 5.5 5 3.5 2 3.9 4 3 2.4 2.1 1.2 2.1 3.0 0.1 1.3 1.4 2.5 0.5
     Left                                  
          Frontal 2.5 4.0 2.5 3.2 2.2 4.8 2.4 1.0 2.3 1.5 1.7 3.0 0.3 1.6 1.7 2.5 0.5
          Parietal 1.9 5.8 3.1 2.9 4.1 4.5 3.5 2.7 2.8 1.5 2.0 2.0 0.2 1.9 2.2 2,8 0.4
          Occipital 5.0 5.3 2.3 2 2.8 3.9 3.1 1.1 2.1 1.2 1.7 3.8 0.3 1.0 1.8 1.7 0.3
Total (mean) 3.7 4.7 2.5 2.4 3.4 4.1 3.3 1.6 2.2 1.3 1.8 2.9 0.2 1.4 1.5 2.2 0.5
CBF (mlblood/100 gtissue min)                                  
     Right                                  
          Frontal 18.6 32.8 4.2 8.6 34.1 42.8 53 35.2 44.1 27.9 30 46.9 1.1 38.4 28.8 37.2 10.1
          Parietal 35.6 30 10.6 15.6 33.3 12 41 29.4 42.3 31.2 29 52.8 2.3 33.2 27.4 36.4 12.3
          Occipital 31.8 30 17.4 11.8 33.4 31.9 48 36.2 48.4 26.5 31 63.3 2.5 38.2 31.3 38.6 3.9
     Left                                  
          Frontal 19.5 33.2 5.3 9.5 16.3 44.7 42.3 26.7 43.7 32.5 13.8 62.3 5.1 29.1 26.4 37.4 12.8
          Parietal 15.9 33 12.9 15.9 11.4 42.9 41 42.3 45.9 33.4 14.1 62.9 5.7 47.6 33.4 40.6 9.9
          Occipital 34.5 33 17.5 14.5 36.1 41.5 35 33.9 45.3 25.7 21 57.2 10.1 30.1 30.4 34.9 8.3
Total (mean) 25.9 32 11.3 12.6 27.4 35.9 43.3 33.9 44.9 29.5 23.1 57.5 4.4 36.1 29.6 37.5 9.5
MTT (sec)                                  
     Right                                  
          Frontal 9.1 7.3 5 4.1 10.9 4 3.9 2.4 3.1 3.0 3.2 3.8 8.9 3.2 3.0 3.2 4.1
          Parietal 8.2 9.3 7.4 4.2 8.7 3.9 4 3.2 2.9 2.2 3.9 3.1 2.2 2.9 2.2 3.5 3.8
          Occipital 10.5 10 6 4.5 7.1 4 4.9 4 2.7 2.6 4.2 2.9 3.6 2.1 2.7 4 8.1
     Left                                  
          Frontal 7.9 7.4 5.3 7.9 9.1 3.9 3.8 2.3 3.2 2.9 7.8 2.9 3.8 3.3 3.9 4.1 2.5
          Parietal 7.4 9.6 2.5 7.4 6 4.7 4.1 3.9 3.7 2.7 8.9 2.0 2.9 2.4 4.1 4.2 3.0
          Occipital 8.7 9.7 6.3 8.7 5.2 3.8 4.2 2.0 2.8 3.0 5 4 3.1 2.1 3.6 3.0 2.7
Total (mean) 8.6 8.8 5.4 6.1 7.8 4.0 4.1 2.9 3.0 2.7 5.5 3.4 4 2.6 3.3 3.5 3.8
Table III Continued.
  Patient no.
Parameters 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
CBV (mlblood/100 gtissue)                                  
     Right                                  
          Frontal 1.2 3.5 1.9 0.4 2.8 1.7 1.1 0.8 1.7 1.7 1.9 0.8 1.3 1.7 2.3 0.4 1.8
          Parietal 0.7 3 1.8 0.5 3.4 2.1 1.1 0.4 1.3 3.4 1.9 1.1 1.4 1.2 2.4 0.6 2.5
          Occipital 1.3 3.5 2.0 0.5 3.1 1.5 0.8 0.2 1.5 3.0 2.3 1.0 0.8 1.8 1.8 0.4 1.9
     Left                                  
          Frontal 1.6 3.5 1.5 0.6 3.2 2.7 0.3 1.3 1.4 1.3 2.1 0.8 0.4 1.4 2.6 0.7 1.7
          Parietal 1.1 3.7 1.9 0.4 1.6 2.5 1.1 0.7 1.6 3.6 1.8 0.4 0.5 2.2 2.9 0.9 2.7
          Occipital 1.7 3.4 1.6 0.8 2.9 2.4 1.0 0.6 1.4 2.2 2.3 0.6 0.7 1.6 2.7 1 1.6
Total (mean) 1.2 3.4 1.7 0.5 2.6 2.1 0.9 0.6 1.4 2.5 2.0 0.7 0.8 1.6 2.4 0.6 2.0
CBF (mlblood/100 gtissue min)                                  
     Right                                  
          Frontal 26.2 55.8 28.2 2.9 44.1 38 16.9 13.2 28.4 45 36.8 17.8 22.3 33.2 38.5 3.1 38.9
          Parietal 25.8 56.3 27.1 3.5 53.9 39.7 17.1 2.9 27.6 55.2 36.3 18.4 20.8 29.4 39.6 12.7 41.7
          Occipital 27.2 55.7 38.1 8.4 45.9 37 17.3 1.1 24.6 44.7 36.7 16.3 21.9 34.7 38.3 11.6 39.4
     Left                                  
          Frontal 24.7 66.6 28.7 14.8 52.1 39.5 1.9 22.2 25.4 34.5 35.2 12.8 3.5 28.1 47.4 15.3 37.6
          Parietal 24.9 56.4 30.3 13.9 43.7 37.9 16.3 12.9 25.5 51.3 37.4 2.4 3.9 31.9 39.7 14.9 42.9
          Occipital 26.4 60.3 29.2 12.5 43.8 37 16 16.4 26.4 46.6 35.8 13.2 12.6 30.1 41.8 16 38.2
Total (mean) 25.8 58.5 30.2 9.3 47.2 38.1 14.2 11.4 26.3 46.2 36.3 13.4 14.1 31.2 40.8 12.2 39.7
MTT (sec)                                  
     Right                                  
          Frontal 2.9 3.8 4.2 10.1 3.9 2.7 4 3.9 3.8 2.3 3.2 2.9 3.5 3.2 3.7 8.9 2.9
          Parietal 1.8 3.2 4 9.8 3.8 3.3 3.9 9.7 2.9 3.8 3.3 3.9 4.1 2.5 3.7 3.1 3.6
          Occipital 2.9 3.8 3.3 3.9 4.1 2.5 2.8 8.8 3.7 4.1 3.9 3.8 2.3 3.2 2.9 2.5 2.9
     Left                                  
          Frontal 4.0 3.2 3.3 2.8 3.8 4.2 10.2 3.6 3.5 2.4 3.7 4.1 7.7 3 3.4 3.1 2.7
          Parietal 2.8 4 3.9 1.9 2.2 4 4.2 3.5 3.9 4.3 3 10.2 8.2 4.3 4.5 3.9 3.8
          Occipital 3.9 3.4 3.3 3.9 4.1 3.9 3.8 2.3 3.2 2.9 4 2.9 3.8 3.3 3.9 4.1 2.5
Total (mean) 3 3.5 3.6 5.4 3.6 3.4 4.8 5.3 3.5 3.3 3.5 4.6 4.9 3.6 3.6 4.2 3

CTP, computed tomography perfusion; CBF, cerebral blood flow; CBV, cerebral blood volume; MTT, mean transit time.

ROC analysis.

Name Total CBF (mlblood/100 gtissue min) Total CBV (mlblood/100 gtissue) Total MTT (sec) Total PI (cm/sec) Total PSV (cm/sec)
Area 0.896 0.254 0.829 0.671 0.727
Std Error 0.055 0.093 0.079 0.093 0.087
P-value 0.000 0.016 0.001 0.093 0.026

ROC, receiver operating characteristic; PI, pulsatility index; PSV, peak systolic velocity; CBF, cerebral blood flow; CBV, cerebral blood volume; MTT, mean transit time; Std, standard.

Univariate analysis (outcome, ischemic event at 1 month).

Parameter Patients with an ischemic event Patients without an ischemic event P-value
Age 57.8±22 52.0±15 0.248
Blood pressure 91.2±9 95.7±11 0.203
GCS 13.3±2 12.9±2 0.367
Total PSV (cm/sec) 108.08±25.63 87.38±24.29 0.023
Total PI (cm/sec) 0.97±0.18 0.89±0.12 0.097
CBF (mlblood/100 gtissue min) 22.59±5.65 12.81±12.08 0.003
CBV (mlblood/100 gtissue min) 2.22±0.73 1.10±1.14 0.004
MTT (sec) 3.85±1.57 4.94±1.35 0.001

All data are presented as the mean ± SD. CBF, cerebral blood flow; CBV, cerebral blood volume; GCS, Glasgow coma scale; MTT, mean transit time; PI, pulsatility index; PSV, peak systolic velocity; SD, standard deviation.

Multivariate analysis (outcome, ischemic event at 1 month).

  95% CI for Exp(B)
Parameter P-value Exp(B) Lower Upper
Total PSV mean (cm/sec) 0.331 1.054 0.948  
CBV mean (mlblood/100 gtissue min) 0.926 0.900 1.005 1.105
CBF mean (mlblood/100 gtissue min) 0.003 1.150 1.197 8.337
MTT mean (sec) 0.614 0.774 0.943 1.402

CBF, cerebral blood flow; CBV, cerebral blood volume MTT, mean transit time; CI, confidence interval; PSV, peak systolic velocity.